Kalaris Announces Upcoming Presentation of TH103 Phase 1a Clinical Data at American Society of Retina Specialists; Ph 1b/2 Clinical Trial Actively Enrolling

Kalaris Therapeutics announced it will present Phase 1a clinical data for TH103, a novel dual-targeting VEGF/HSPG biologic, at the American Society of Retina Specialists 2026 Annual Meeting on July 17, 2026. The company's Phase 1b/2 multiple ascending dose study for neovascular age-related macular degeneration is actively enrolling patients, with initial data expected in the first half of 2027.